Consensus statement on the use of Xelma in diabetic foot ulcers

Alistair Mcinnes

Research output: Contribution to journalArticlepeer-review


Diabetic foot ulcers are a common and costly complication of diabetes, often presenting in a chronic wound state. Adjuvant therapies may be used to kick-start the healing process in hard-to-heal and chronic wounds, but specific placement of these therapies in the care pathway is not always clear. A group of experienced clinicians developed the following consensus statement and treatment algorithm on the use of the extracellular matrix protein therapy Xelma (Mölnlycke Health Care, Dunstable) specifically in diabetic foot ulcers.
Original languageEnglish
Pages (from-to)148-151
Number of pages4
JournalDiabetic Foot
Issue number3
Publication statusPublished - 1 Jan 2010


Dive into the research topics of 'Consensus statement on the use of Xelma in diabetic foot ulcers'. Together they form a unique fingerprint.

Cite this